Cancer
Researchers from the State Key Laboratory of Molecular Oncology have made significant strides in personalized medicine, focusing on the identification and targeting of neoantigens in solid tumors. This promising approach utilizes T cell receptor (TCR-T) cells, engineered to selectively kill tumor cells while minimizing damage to healthy cells. The study,
Cancer
Researchers from the State Key Laboratory of Molecular Oncology have made significant strides in personalized medicine, focusing on the identification and targeting of neoantigens in solid tumors. This promising approach utilizes T cell receptor (TCR-T) cells, engineered to selectively kill tumor cells while minimizing damage to healthy cells. The study,
Cancer
Researchers from the State Key Laboratory of Molecular Oncology have made significant strides in personalized medicine, focusing on the identification and targeting of neoantigens in solid tumors. This promising approach utilizes T cell receptor (TCR-T) cells, engineered to selectively kill tumor cells while minimizing damage to healthy cells. The study,
Cancer
A recent study published in the JMIR Cancer journal has found that publicly available information on genomic medicine at National Cancer Institute-designated cancer centers (NCI-CCs) in the United States is often lacking. Despite efforts to provide personalized care and incorporate genetic testing, many centers fail to publicly communicate their efforts
Atopic dermatitis
Research led by Inner Mongolia University of Science and Technology in Baotou, People's Republic of China, has shed light on the intricate mechanisms of mast cell regulation in skin inflammation. The study, published in Frontiers in Immunology, uncovered the functional heterogeneity of mast cells and their distinct inflammatory
Atopic dermatitis
Research led by Inner Mongolia University of Science and Technology in Baotou, People's Republic of China, has shed light on the intricate mechanisms of mast cell regulation in skin inflammation. The study, published in Frontiers in Immunology, uncovered the functional heterogeneity of mast cells and their distinct inflammatory
Investor relations
IDEAYA Biosciences, a precision medicine oncology company, will participate in two upcoming investor relations events. The company will host a fireside chat at Citi's 2025 SMID Cap Biopharma Call Series on November 6, 2025, and another at the Jefferies Global Healthcare Conference in London on November 18, 2025.
Precision medicine
A groundbreaking collaboration between precision oncology company Guardant Health and AI leader Zephyr AI aims to unlock new insights for personalized oncology treatments. By combining Guardant's industry-leading molecular data with Zephyr's advanced analytics platform, the partnership will accelerate research and development for biopharma partners, generating predictions
Electronic evidence
Researchers at Central China Normal University conducted a study to investigate the factors that influence the continued usage intention of AI-based wearable devices. The study proposes a novel theoretical model based on the attitude-behavior-context (ABC) theoretical framework to explore the effects of technological and gamification factors on continued usage intention.
Pharmacogenomics
Researchers from the Molecular Genetics Laboratory have developed a novel assay that simultaneously detects mutations, immunoglobulin (IG) fusions, and IG V(D)J clonality in plasma and cerebrospinal fluid (CSF) to enhance molecular profiling and CNS monitoring in diffuse large B-cell lymphoma (DLBCL) patients. This non-invasive approach offers improved sensitivity
Precision medicine
Investigators from the Department of Health Education, Shanghai Health and Medical Center, have made groundbreaking findings in the application of artificial intelligence (AI) agents in medical diagnosis and personalized treatment planning. By integrating cognitive reasoning with actionable decision-making, these agents have achieved notable diagnostic accuracy and optimized treatment strategies. The
Precision medicine
A recent study published in Neuro-Oncology has identified novel genomic associations with brain metastasis and progression in colorectal cancer, offering a potential basis for personalized clinical management. Researchers at Memorial Sloan-Kettering Cancer Center analyzed next-generation sequencing data from patients with colorectal cancer to identify genomic features associated with brain metastasis
